A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis [The AIRTIVITYâ„¢ Study] (NCT06872892)

AIRTIVITY is a study to find out whether BI 1291583 helps people with bronchiectasis.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Peter Wark

Key inclusion data

Must be male or female over the age of 18. Must have a diagnosis of bronchiectasis. Must have had at least 1-2 pulmonary exacerbations requiring antibiotic treatment in the past 12 months. Must not be pregnant or have smoked over the past 3 months, must not have had major surgery in the past 6 weeks or participated in another trial in the past. Must not have tuberculosis or mycobacteria requiring treatment.